Site Editor

Thomas Flaig, MD


ASCO 2022: Tislelizumab Plus Nab-Paclitaxel Under Study in Urothelial Bladder Cancer

By: Vanessa A. Carter, BS
Posted: Friday, June 24, 2022

HaiTao Wang, MD, MS, PhD, of Tianjin Medical University, China, and colleagues aimed to elucidate the efficacy and safety of combining the monoclonal antibody tislelizumab with nab-paclitaxel in patients with non–muscle-invasive urothelial bladder carcinoma. The preliminary data and exploratory work of the phase II TRUCE-02 trial were presented during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 4507).

“Tislelizumab with nab-paclitaxel represents a novel treatment option with a satisfactory benefit in treating non–muscle-invasive bladder cancer,” concluded the study authors. “Whole-genome sequencing results also showed there are mutation markers that may predict whether patients would benefit from this treatment plan.”

This open-label, single-arm study enrolled 54 patients with tumors that were not completely resectable by transurethral resection. Participants who met study criteria received 200 mg of tislelizumab plus 200 mg of nab-paclitaxel for three or four cycles, followed by comprehensive imageology, urine cytology, and pathology assessments.

A total of 42 patients completed the entire three- or four-treatment cycles and reached the primary study endpoint; 23 participants achieved a complete response. With an objective response rate of 60%, 33 individuals have been able to avoid cystectomy thus far. Notably, the rate of grade 3 or 4 adverse events was lower than 2%. Furthermore, urine cytology and fluorescence in situ hybridization demonstrated diagnostic efficiencies of 68.4% and 45.7% before pathologic assessment, respectively.

Regarding PD-L1, 47.3% of patients achieving a complete or partial response and 50% of those who were unresponsive tested positive for PD-L1 expression. In addition, sequencing results uncovered that the protein TCF7L2 may be a potential marker in predicting adverse outcomes for individuals in this population. Also, homologous recombination repair mutations may predict the prognosis of bladder cancer and help to guide therapeutic options.

Disclosure: The study authors reported no conflicts of interest.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.